Febuxostat: a new treatment for hyperuricaemia in gout

Febuxostat is a new non-purine xanthine oxidase inhibitor that is more potent than allopurinol 300 mg daily. In two Phase III trials, significantly more febuxostat-treated gout patients met the primary endpoint [serum urate (sUA)

Saved in:
Bibliographic Details
Published in:Rheumatology (Oxford, England) England), 2009-05, Vol.48 (suppl-2), p.ii15-ii19
Main Author: Edwards, N. Lawrence
Format: Article
Language:English
Subjects:
Adverse events
Allopurinol
Allopurinol - therapeutic use
Clinical studies
Febuxostat
Gout
Gout - drug therapy
Gout - etiology
Gout Suppressants - adverse effects
Gout Suppressants - pharmacology
Gout Suppressants - therapeutic use
Humans
Hyperuricemia - complications
Hyperuricemia - drug therapy
Randomized Controlled Trials as Topic
sUA target
Thiazoles - adverse effects
Thiazoles - pharmacology
Thiazoles - therapeutic use
Urate-lowering therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Febuxostat is a new non-purine xanthine oxidase inhibitor that is more potent than allopurinol 300 mg daily. In two Phase III trials, significantly more febuxostat-treated gout patients met the primary endpoint [serum urate (sUA)
ISSN:1462-0324
1462-0332
DOI:10.1093/rheumatology/kep088